Styrylboronic Acid

Styrylboronic Acid

SCHEMBL4168786

OB(O)/C=C\c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 5/20 1.00
MGLL Q99685 1/20 0.75
MAOB P27338 2/20 0.50
CA2 P00918 2/20 0.48
ARG2 P78540 1/20 0.46
ALDH1A1 P00352 2/20 0.46
LMNA P02545 2/20 0.46
HDAC3 O15379 2/20 0.46
HDAC4 P56524 2/20 0.46
HDAC1 Q13547 2/20 0.46
HDAC2 Q92769 2/20 0.46
HDAC8 Q9BY41 2/20 0.46
HDAC6 Q9UBN7 2/20 0.46
TNKS O95271 1/20 0.46
HCAR2 Q8TDS4 1/20 0.46
HDAC7 Q8WUI4 1/20 0.46
HDAC10 Q969S8 1/20 0.46
HDAC11 Q96DB2 1/20 0.46
TNKS2 Q9H2K2 1/20 0.46
HDAC9 Q9UKV0 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Styrylboronic Acid SCHEMBL144460 1.00 CA1 (1.00) CA1MGLLMAOBCA2ARG2
Styrylboronic Acid SCHEMBL144461 1.00 CA1 (1.00) CA1MGLLMAOBCA2ARG2
Styrylboronic Acid SCHEMBL4390084 0.97 CA1 (0.95) CA1MGLLMAOBCA2ARG2
Styrylboronic Acid SCHEMBL28579652 0.87 CA1 (0.76) CA1MGLLMAOBCA2ARG2
SCHEMBL2910475 0.86 CA1 (1.00) CA1MGLLMAOBCA2ARG2
SCHEMBL12260418 0.86 CA1 (1.00) CA1MGLLMAOBCA2ARG2
SCHEMBL8011423 0.84 CA1 (0.73) CA1MGLLMAOBALDH1A1LMNA
(Z)-1,2-Diphenylethene SCHEMBL29134000 0.76 MAOB (0.69) CA1MAOBALDH1A1LMNAHDAC3
SCHEMBL23044739 0.75 CA1 (0.61) CA1MGLLMAOBCA2MAPT
SCHEMBL13204210 0.75 CA1 (0.61) CA1MGLLCA2TRPA1NFE2L2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12441669-B2 PCNHCP metal complexes and uses thereof TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) 2025-10-14 US disclosed
CN-117756303-A Preparation method of composite scale and corrosion inhibitor for water treatment 佛山市栢豪环保科技有限公司 2024-03-26 CN disclosed
US-20230322647-A1 PCNHCP METAL COMPLEXES AND USES THEREOF TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) 2023-10-12 US disclosed
WO-2022043993-A1 PCNHCP METAL COMPLEXES AND USES THEREOF TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) 2022-03-03 WO disclosed
US-20180327355-A1 ISOINDOLINE DERIVATIVES VIIV HEALTHCARE UK LIMITED (GB) 2018-11-15 US disclosed
US-20160126478-A1 EMISSIVE COMPOUNDS FOR LIGHT EMITTING DEVICES NITTO DENKO CORPORATION (JP) 2016-05-05 US disclosed
US-20090004185-A1 AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF BETA-CATENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS WYETH (US) 2009-01-01 US disclosed
US-20080306127-A9 Compounds and methods for inhibiting the interaction of BCL proteins with binding partners INFINITY PHARMACEUTICALS, INC. (US) 2008-12-11 US disclosed
US-20070161690-A1 Compounds and methods for inhibiting the interaction of BCL proteins with binding partners INFINITY PHARMACEUTICALS, INC. (US) 2007-07-12 US disclosed
US-20060020004-A1 Isoxazolidine compounds for treatment of bacterial infections INFINITY PHARMACEUTICALS, INC. (US) 2006-01-26 US disclosed
WO-2006009907-A2 ISOXAZOLIDINE COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS INFINITY PHARMACEUTICALS, INC. (US) 2006-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060020004-A1 Isoxazolidine compounds for treatment of bacterial infections QDPR, NQO2, SQLE CA1 4344/4885MGLL 1990/4885MAOB 160/4885
US-20230322647-A1 PCNHCP METAL COMPLEXES AND USES THEREOF PIN4, HIRIP3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 CA1 728/4885MGLL 4059/4885MAOB 3332/4885
US-20090004185-A1 AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF BETA-CATENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS TCF4, CTNNB1, TCF7 CA1 4688/4885MGLL 4367/4885MAOB 3491/4885
US-20080306127-A9 Compounds and methods for inhibiting the interaction of BCL proteins with binding partners BCL3, BCL2, BCLAF1 CA1 2898/4885MGLL 4034/4885MAOB 3618/4885
US-20180327355-A1 ISOINDOLINE DERIVATIVES IRF3, EIF2AK2, MAVS CA1 4024/4885MGLL 3447/4885MAOB 857/4885
US-20070161690-A1 Compounds and methods for inhibiting the interaction of BCL proteins with binding partners BCL3, BCL2, BCLAF1 CA1 2898/4885MGLL 4034/4885MAOB 3618/4885
US-12441669-B2 PCNHCP metal complexes and uses thereof PIN4, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HIRIP3 CA1 755/4885MGLL 3886/4885MAOB 2826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.